四价流感亚单位灭活疫苗随机双盲对照Ⅰ期临床试验
该随机双盲主动对照Ⅰ期试验纳入320名受试者,按年龄分4组,比较全剂量亚单位无佐剂四价流感疫苗与已上市裂解疫苗(≥3岁)及半剂量疫苗(6-35月龄)的安全性和免疫原性。结果显示不良反应轻微自限,≥3岁组全身反应率15.0%对19.2%(p=0.391),各型血清保护率与对照相当;6-35月龄组全剂量安全性相当且对BV型血清保护率优于半剂量(75%对29.7%,p<0.001)。
要点
- 全剂量亚单位四价流感疫苗在≥3岁人群中安全性与裂解疫苗相当,免疫原性非劣。
- 6-35月龄幼儿中,全剂量疫苗对BV型血清保护率显著优于半剂量(75%对29.7%)。
- 所有不良反应罕见、轻微且自限。
核心结论
- 全剂量亚单位无佐剂四价流感疫苗安全有效,可提供更广泛的流感病毒保护。
研究设计与样本
- 随机、双盲、主动对照Ⅰ期临床试验,共320名受试者,按年龄分4组(6-35月龄、3-8岁、9-17岁、≥18岁),每组80人。
- ≥3岁组接种1剂,6-35月龄组接种2剂(第0天和第28天),比较试验疫苗与已上市裂解疫苗或半剂量疫苗。
主要发现
- ≥3岁组全剂量亚单位疫苗全身不良反应率15.0%(95%CI 8.6-21.4),对照组19.2%(95%CI 12.1-26.2),p=0.391。
- ≥3岁组血清保护率:H1N1 99.2%对94.9%(p=0.117),H3N2 81.7%对82.1%(p=0.939),BV 75.8%对74.4%(p=0.793),BY 94.2%对92.3%(p=0.568)。
- 6-35月龄组总不良反应率37.5%(95%CI 18.5-56.5)对47.5%(95%CI 26.1-68.9),p=0.366。
- 6-35月龄组血清保护率:BV 75%对29.7%(p<0.001),H1N1 85%对75.7%(p=0.117),H3N2 50%对29.7%(p=0.070),BY 75%对56.8%(p=0.091)。
临床怎么用
- 全剂量亚单位四价流感疫苗可作为≥3岁人群的流感预防选择,尤其对幼儿BV型保护更优。
- 在6-35月龄幼儿中,全剂量方案比半剂量方案可能提供更好的BV型保护。
局限性
- 为Ⅰ期临床试验,样本量有限,需进一步扩大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Quadrivalent influenza inactivated vaccine (IIV4) is more likely to provide wider protection against yearly circulating influenza viruses than trivalent inactivated influenza vaccine (IIV3). In this study, a total of 320 participants were allocated to four age cohorts (6-35 months, 3-8 years, 9-17 years, and ≥ 18 years; 80 participants/cohort) according to their actual date of birth. Participants in each cohort were randomly assigned to two groups to receive intramuscular injection of the trial vaccine or the comparative vaccine in a one-dose (3-8 years, 9-17 years,and ≥ 18 years) schedule on day 0 or two-dose (6-35 months cohort) schedule on day 0 and 28. The first objective is to evaluate the safety and immunogenicity of the full-dose subunit non-adjuvanted IIV4 (FD-subunit NAIIV4) we developed versus an active-control, China-licensed split-virion NAIIV4, in people ≥ 3 years. The second objective is to evaluate the safety and immunogenicity of FD-subunit NAIIV4 versus the half-dose (HD-subunit NAIIV4) in toddlers aged 6-35 months. Results showed that all adverse reactions noted were rare, mild, and self-limited. In ≥ 3 years cohorts, systemic adverse reactions in FD-subunit NAIIV4 groups were less than the active control split-virion NAIIV4 groups ([Systemic adverse reaction rates (95%CI)], 15.0 (8.6-21.4) versus 19.2(12.1-26.2), p = 0.391). The overall seroprotection efficacy after vaccination were comparable between FD-subunit NAIIV4 and the active control split-virion NAIIV4([Seroprotection rates (95%CI)], H1N1, 99.2(81.3-100.0) versus 94.9(90.9-98.9), p = 0.117; H3N2, 81.7(74.7-88.6) versus 82.1(75.1-89.0), p = 0.939; BV, 75.8(68.2-83.5) versus 74.4(66.4-82.3), p = 0.793; BY, 94.2(90.0-98.4) versus 92.3(87.5-97.1), p = 0.568). Additionally, FD-subunit NAIIV4 has comparable safety and better seroprotection versus that of the half-dose in 6-35 months toddlers groups ([Total adverse reaction rates (95%CI)], 37.5(18.5-56.5) versus 47.5(26.1-68.9), p = 0.366) ([Seroprotection rates (95%CI)], H1N1, 85(56.4-100.0) versus 75.7(47.6-100.0), p = 0.117; H3N2, 50(28.1-71.9) versus 29.7(12.2-47.3), p = 0.070; BV, 75(48.2-100.0) versus 29.7(12.2-47.3), p < 0.001; BY, 75(48.2-100.0) versus 56.8(32.5-81.0), p = 0.091). As a result, the FD-subunit NAIIV4 we developed is safe and effective to provide broader and adequate protection against the circulating influenza viruses during 2018-2019, which could be an essential component of the global preventive strategy for influenza pandemic.
引用
- Wang Y, Zhang Y, Wu H, et al. Safety and immunogenicity of a quadrivalent inactivated subunit non-adjuvanted influenza vaccine: A randomized, double-blind, active-controlled phase 1 clinical trial. Vaccine. 2021. PMID: 34088505. doi:10.1016/j.vaccine.2021.05.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。